- Home
- RGC vs VIGL Comparison
RGC vs VIGL Comparison
Compare RGC & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- VIGL
- Stock Information
- Founded
- RGC 2014
- VIGL 2020
- Country
- RGC Hong Kong
- VIGL United States
- Employees
- RGC N/A
- VIGL N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- VIGL Health Care
- Exchange
- RGC Nasdaq
- VIGL Nasdaq
- Market Cap
- RGC 171.1M
- VIGL 148.7M
- IPO Year
- RGC 2021
- VIGL 2022
- Fundamental
- Price
- RGC $5.32
- VIGL $3.74
- Analyst Decision
- RGC
- VIGL Buy
- Analyst Count
- RGC 0
- VIGL 5
- Target Price
- RGC N/A
- VIGL $16.60
- AVG Volume (30 Days)
- RGC 29.9K
- VIGL 98.6K
- Earning Date
- RGC 10-25-2024
- VIGL 08-13-2024
- Dividend Yield
- RGC N/A
- VIGL N/A
- EPS Growth
- RGC N/A
- VIGL N/A
- EPS
- RGC N/A
- VIGL N/A
- Revenue
- RGC N/A
- VIGL N/A
- Revenue This Year
- RGC N/A
- VIGL N/A
- Revenue Next Year
- RGC N/A
- VIGL N/A
- P/E Ratio
- RGC N/A
- VIGL N/A
- Revenue Growth
- RGC N/A
- VIGL N/A
- 52 Week Low
- RGC $3.03
- VIGL $2.47
- 52 Week High
- RGC $32.44
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- RGC 38.69
- VIGL 53.60
- Support Level
- RGC $5.52
- VIGL $3.66
- Resistance Level
- RGC $6.57
- VIGL $4.03
- Average True Range (ATR)
- RGC 0.76
- VIGL 0.28
- MACD
- RGC -0.27
- VIGL 0.05
- Stochastic Oscillator
- RGC 0.00
- VIGL 65.06
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.